יחס חוב לטווח ארוך להון Geron Bio (GERN)

This GURU.Markets price chart for Geron Corporation (GERN) reflects the price action of an asset valued at 1.08. Geron Corporation (GERN) maintains a monopoly in the treatment of hematologic malignancies due to a unique inhibitor and patent protection. Meanwhile, AI is accelerating the discovery of new molecules, although final tests still require physicians. Fully utilized partner plants with functional equipment guarantee production stability.

It is critically important for Geron Corporation (GERN) to maintain liquidity to support the expansion of Rytelo and conduct new clinical trials. By analyzing the dynamics of long-term debt-to-equity, an investor assesses the proportion of liabilities with a maturity of over one year relative to the enterprise value, which determines the balance between financial leverage for growth and default risk, confirming the overall stability of the capital structure.